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Abstract
The receptor activator of nuclear factor-κB ligand (RANKL) modulates energy metabolism. However, how
RANKL regulates energy homeostasis is still not clear. This study aims to investigate the central
mechanisms by which central administration of RANKL inhibits food intake and causes weight loss in
mice. We carried out a systematic and in-depth analysis of the neuronal pathways by which RANKL
mediates catabolic effects. After intracerebroventricle (i.c.v.) injection of RANKL, the expression of
neuropeptide Y (NPY) mRNA in the Arc was significantly decreased, while the CART mRNA expression
dramatically increased in the Arc and DMH. However, the agouti-related protein (AgRP) and proopiomelanocortin (POMC) mRNA had no significant changes compared with control groups. Together, the
results suggest that central administration of RANKL reduces food intake and causes weight loss via
modulating the hypothalamic NPY/CART pathways.
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Abstract
The receptor activator of nuclear factor-κB ligand (RANKL) modulates energy metabolism.
However, how RANKL regulates energy homeostasis is still not clear. This study aims to investigate
the central mechanisms by which central administration of RANKL inhibits food intake and causes
weight loss in mice. We carried out a systematic and in-depth analysis of the neuronal pathways by
which RANKL mediates catabolic effects. After intracerebroventricle (i.c.v.) injection of RANKL, the
expression of neuropeptide Y (NPY) mRNA in the Arc was significantly decreased, while the CART
mRNA expression dramatically increased in the Arc and DMH. However, the agouti-related protein
(AgRP) and pro-opiomelanocortin (POMC) mRNA had no significant changes compared with
control groups. Together, the results suggest that central administration of RANKL reduces food
intake and causes weight loss via modulating the hypothalamic NPY/CART pathways.
Key words: Receptor activator of NF-κB ligand; Food intake; Cocaine- and amphetamine-regulated transcript;
Neuropeptide Y; Hypothalamus

Introduction
About 500 million adults have developed obesity
worldwide, which is associated with a greater risk of
type II diabetes and cardiovascular disease that makes
obesity as a major health, social and economic
problems to most countries [1-3]. Various brain nuclei
are involved in the control of body metabolisms,
including insulin production and energy expenditure
[4, 5]. Recent studies have proved a link between the
central RANKL/RANK and energy homeostasis [6, 7].
RANKL is a 317-amino acid peptide that belongs to
tumour necrosis factor (TNF) cytokine family [8]. Two
forms
of
RANKL
have
been
found,
a
membrane-bound molecule expressed on osteoblasts
and a soluble form. RANKL plays an important role
in bone reconstruction by binding and activating its
receptor RANK, a 616-amino acid peptide [9, 10].
RANKL/RANK protein and mRNA are expressed in

bone and bone marrow, lymphoid tissues [11], the
hypothalamus and septal regions of the brain [6, 7].
Importantly, elevated levels of circulating soluble
RANKL have been observed in the circulation of
patients with anorexia nervosa compared to healthy,
age-matched controls [12] and it is worth noting that
RANKL levels depend on the severity of the anorexia
nervosa [13]. Similarly, mice intraperitoneally injected
with an adenovirus vector harbouring murine soluble
RANKL cDNA exhibit reduced food intake and body
weight [14]. Together, these findings support
anorectic effects of RANKL. However, the precise
hypothalamic nuclei and neuropeptides that mediate
the effects of RANKL remain unexplored.
Arcuate (Arc) and dorsomedial (DMH) nuclei in
the hypothalamus are two main areas regulating
energy and appetite. These nuclei in the Arc
http://www.medsci.org
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interchange and integrate peripheral signals like
calories intake, nutritional status to regulate appetite
and energy expenditure [4, 15, 16]. Previous studies
have shown a link between the DMH, ingestion and
body weight regulation [17]. Lesion of the DMH
results in hypophagia, reduced body weight and
impaired growth in rats [18]. In the Arc, two types of
neurons, NPY/agouti-related protein (AgRP) neurons
and CART/pro-opiomelanocortin (POMC), are main
functional units to produce orexigenic or anorexigenic
neurotransmitters respectively [19, 20]. NPY is a
36-amino acid peptide that drives body weight gain,
increased food intake and decreased energy
expenditure [4, 21, 22], while CART causes loss of
appetite. Studies on bone remodelling reveal that
RANKL signalling is modulated by CART and NPY.
For instance, homozygous deletion of CART results in
increased RANKL expression in bone and decreased
bone mass [23], while NPY inhibits RANKL
expression on osteoblasts [24]. However, the
relationship among CART, NPY and RANKL in the
regulation of energy balance remains to be addressed.
A major goal of this study is to explore whether
RANKL reduces food intake and causes body weight
loss via modulating the hypothalamic NPY/CART
neuronal pathways.

Materials and Methods
Ethical and animal care
The experimental protocol was approved by the
Third Military Medical University Animal Care
Committee according to the National Institutes of
Health Guide for the Care and Use of Laboratory
Animals (NIH publication number 8023). All mice
were housed under conditions of controlled
temperature (22°C) and illumination (12-hour light
cycle, lights on at 07:00 am) with ad libitum access to
water and normal chow (6% calories from fat, 21%
calories from protein, 71% calories from carbohydrate,
Gordon’s Specialty Stock Feeds, Australia) unless
otherwise stated.

Body weight, food intake measurement
Eleven C57BL/6J male mice were divided into
two groups, treated with either RANKL
(intracerebroventricle, i.c.v. injection, n=6) or saline as
control group (n=5). After three days of
acclimatization,
we
implanted
ALZET®
Micro-Osmotic Pump (LOT NO. 10239-10, Model
1007D, Flow rate 0.5μl/hour) in mice for RANKL i.c.v.
injection which contained RANKL (7 days) and
allowed for a constant stream of 10 ng per day
RANKL to be delivered directly into the third
ventricle of brain. The procedure of the
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Micro-Osmotic Pump implantation was performed as
described in previous study [25]. Meanwhile, we
applied the same surgery to the other group, in which
pump contained saline as controls. The subsequent
measurement of body weight was taken daily at the
same time. At the 8th day, cumulative food intake in 24
hours (from 7th day 10:00 to 8th day 10:00) of two
groups was calculated separately. Both groups of
mice were used for the detection of in situ
hybridization mRNA expression.

Immunohistologic analysis of RANKL altered
c-fos expression in brain
At the age of 16 weeks, ten C57BL/6J male mice
were divided into two groups: one group of mice for
RANKL i.v. injection (n=5) and the other group of
mice for saline i.v. injection as controls (n=5), and both
groups were used for c-fos detection. The mice were
i.v. injected with 10 µg RANKL diluted in 1ml saline
or 1ml saline for 30 min and then deeply anesthetized
with ketamine-xylazine (100 mg / kg and 20 mg / kg
from Parke Davis Pfizer, Sydney, Australia and Bayer
AG, Leverkusen, Germany, respectively) through
intraperitoneally injection. From the left heart
ventricle, 25ml of phosphate buffered saline (PBS) and
4% paraformaldehyde dissolved in PBS were
perfused into the whole body successively. After
dislocating and sacrificing the mice, we removed the
brain immediately, then placed it in 4%
paraformaldehyde PBS solution for 30 minutes and
transferred to 30% sucrose solution to remain
overnight and restored in -70 °C refrigerator. 30 mm
thickness of coronal slices were placed in PBS and
washed in 50% ethanol which contained 1% H2O2 for
20 minutes to abolish endogenous peroxidase activity.
Brain section was incubated with the primary
antibody, rabbit anti-mouse c-fos protein (Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA) which was
diluted at 1: 4000 in PBS containing 0.1% TRITON
X-100, at room temperature overnight. After washing
in 0.1% TRITON X-100-PBS for 10 minutes and
repeated three times, sections were incubated for 3
hours with the biotinylated secondary antibody
(Sigma-Aldrich, St Louis, MO, USA), diluted at 1:250
in PBS. Again, washing in PBS for 10 minutes 3 times,
brain sections were incubated with Avidin
Biotin-Peroxidase VectastainH (Vector Laboratories,
Burlingame, CA, USA) at room temperature for 30
minutes. Then sections were rinsed in PBS and treated
with diaminobenzidine (Dako, Carpinteria, CA, USA)
for 5 minutes. Finally, sections were rinsed with
water, mounted on slides, and dehydrated before
cover slipping. Sections were visualized for c-fos-like
immunoreactivity by using a Zeiss Axiophot
microscope equipped with the Prog Res digital
http://www.medsci.org
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camera (Carl Zeiss Imaging Solutions GmbH, Munich,
Germany). Semiquantitative analysis of c-fos has been
described previously [4].

Double labelling of c-fos and NPY
In order to verify whether NPY neurons in the
hypothalamus are involved in response to RANKL i.v.
injection, double-labelling experiment was performed
to ascertain whether NPY neurons were activated by
RANKL i.v. injection. At the age of 16 weeks, eight
transgenic NPY Green Fluorescent Protein (GFP) male
mice expressing green fluorescent protein (purchased
from Jackson Laboratory) were divided into two
groups: one group of mice for RANKL i.v. injection
(n=4) and the other group of mice for saline i.v.
injection as controls (n=4), and both group of mice
were used for c-fos detection. These NPYGFP mice
were i.v. injected with 10 µg RANKL diluted in 1 ml
saline or 1 ml saline for 30 min and then sacrificed
after deeply anaesthetized. Following steps were
carried out as c-fos immunohistochemistry test stated
above. Brain section was incubated with the primary
antibody, rabbit anti-mouse c-fos protein (Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA) diluted at
1:4000. The secondary antibody against c-fos
visualizing red fluorescent was Alexa Fluor 594 goat
anti-rabbit IgG (A11037, Life Technologies, Canada)
diluted at 1:250. Sections were mounted with
fluoromount and quantified for c-fos immunoreactivity in NPY-GFP transgenic mice using a ProgRes
3008 camera (Zeiss, Jena, Germany).

Double labelling of c-fos and CART mRNA
In order to determine whether CART neurons in
the hypothalamus are activated by RANKL i.v.
injection, four C57BL/6J male mice, sixteen week old,
were i.v. injected with 10 µg RANKL diluted in 1ml
saline, and another four mice were i.v. injected with
1ml saline as controls. At 30 min after treatment, mice
were deeply anaesthetised, and the brains were fixed
by perfused with 25ml phosphate buffered saline
(PBS) and 4% paraformaldehyde dissolved in PBS.
After soaking in 30% sucrose solution overnight, the
brain was cut into coronal sections of 30μm thickness.
Immunoreactivities of c-fos were carried out as stated
above. Brain sections were incubated with secondary
antibodies, goat anti-rabbit (Sigma-Aldrich, St Louis,
MO, USA), for three hours, which was diluted at 1:250
in PBS. Sections were mounted and CART in situ
hybridisation was performed as previously described
[26]. DNA oligonucleotides complementary to mouse
CART (5’-TCCTTCTCGTGGGACGCATCATCCACG
GCAGAGTAGATGTCC AGG-3’) was labelled with
[35S] thio-dATP. Co-localization of c-fos and CART
mRNA were captured and counted under a Zeiss
Axiophot microscope.
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In Situ Hybridization for Quantification of NPY,
CART, POMC and AgRP mRNA Expression
At the 8th day, all mice treated with RANKL (n=6)
or saline (n=5) from implanted micro-osmotic pump
were deeply anesthetized with ketamine-xylazine
(100 mg / kg and 20 mg / kg from Parke Davis Pfizer,
Sydney, Australia and Bayer AG, Leverkusen,
Germany, respectively) through intraperitoneal
injection. After sacrificing mice with the same
procedure stated above, we cut 20μm coronal slices
and prepared them as described in previous study
[26, 27]. For radioactive in situ hybridization, DNA
oligonucleotides complementary to mouse NPY
(5’-GAGGGTCAGTCCACACAGCCCCATTCGCTTG
TTACCTAGCAT-3’) CART (5’-TCCTTCTCGTGGGA
CGCATCATCCACGGCAGAGTAGATGTCCA
GG-3’), POMC (5’-TGGCTGCTCTCCAGGCACCAG
CTCCACACATCTATGGAG G-3’), or AgRP (5’-AGC
TTGCGGCAGTAGCAAAAGGCATTGAAGAAGCG
GCA GTAGCAC-3’) were labelled with [35S]
thio-dATP (Amersham Biosciences, Little Chalfont,
Buckinghamshire, UK) using terminal deoxynucleotidyl transferase (Roche, Mannheim, Germany). The
mRNA levels of NPY, CART, POMC and AgRP in the
Arc, and CART in the DMH were evaluated,
respectively, by measuring silver grain densities over
individual neurons from photo-emulsion dipped
sections, as described previously [4, 26].

Statistical analysis
All statistical analyses were performed using
GraphPad Prism Version 6.0 (GraphPad Software,
Inc). Differences between means were assessed, as
appropriate, by two- or one-way ANOVA followed
by Bonferroni post hoc analysis. For all statistical
analyses, a P value <0.05 was considered to be
statistically significant. Data were presented as means
± SEM.

Results
Body weight and food intake in response to
RANKL administration
During 7 days of treatment, the mice treated
with RANKL displayed a significant reduction of
body weight compared with controls (Fig. 1A).
Average food intake of each mouse in 24 hours
measured at day 8th showed that the mice treated with
RANKL had lower food intake compared with
controls, which demonstrated that the administration
of central RANKL inhibited food intake (Fig. 1B).

http://www.medsci.org
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generally among the first to be expressed. We
observed that there were significantly more marked
neurons in the section of RANKL treated group than
control group in the Arc (Fig. 2A-C) and DMH (Fig.
2D-F) regions. The elevated expression of c-fos
suggested that neurons in these regions were
activated by RANKL, and revealed that RANKL
might induce changes in NPY and its downstream
signalling pathways.

NPY and CART mRNA co-localised with c-fos
neurons

Figure 1. The body weight and food intake of mice altered after RANKL
injection. Quantifications of body weight and food intake. Data are mean ± SEM. n=6
in RANKL group, n=5 in Saline group ** p<0.001 compared with Saline group.
*p<0.05 compared with Saline group.

Activated c-fos immunoreactive neurons in
hypothalamus after RANKL administration
To clarify which regions of hypothalamus have
been influenced by i.v injection of RANKL, we
examined c-fos immunohistochemistry (Fig. 2). The
c-fos, a proto-oncogene which is referred to as an
immediate early gene for c-fos mRNA and protein, is

Considering that administration of peripheral
RANKL triggered more expression of c-fos gene in the
Arc and DMH, we detected some neuropeptide genes
that regulated energy homeostasis to show which
genes were activated on neurons labelled by c-fos
after i.v injection of RANKL. In the Arc, we found
significant 54% overlap in expression of NPYGFP
neurons (Fig. 3B) and c-fos (Fig. 3A) at 30 min after i.v.
administration of RANKL (Table. 1) (Fig. 3C), which
suggested that NPY-producing cells may be involved
in mediating RANKL-induced decreased appetite and
changes in energy intake. In addition, the
double-labelling
method
combining
c-fos
immunohistochemistry with in situ hybridization
showed that about 72% neurons expressed c-fos
immunoreaction and CART mRNA in the DMH
(Table. 1) (Fig. 4A-B). The expression of CART mRNA
at 30 min after i.v injection of RANKL indicated that
DMH CART neurons were also critical in mediating
anorectic effect of RANKL.

Figure 2. Activated c-fos immunoreactive neurons in the Arc and DMH after RANKL administration. A-F. Immunohistochemical analysis of c-fos expression in
the Arc and DMH after i.v administration of RANKL or saline. The c-fos positive neurons were sharply increased in the Arc (A-C) and DMH (D-F) of RANKL peripheral injection.
Scale bar 100μm. Quantification of c-fos neurons expressed in the Arc and DMH. Data are mean ± SEM of 5 mice each group. *** p<0.001 vs Saline controls. 3V: the third
cerebral ventricle. Arc: Arcuate nucleus.
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Figure 3. NPY co-localised with c-fos neurons in response to RANKL i.v injection. Fluorescent immunohistochemical identification of c-fos and NPY GFP neurons
co-expressed in the Arc, 30 min after RANKL i.v injection. Red staining showed c-fos positive neurons only (A), with green staining indicating NPY neurons expressing GFP (B),
and yellow staining indicating the neurons expressing both c-fos and NPY (C). Scale bar 40μm. (D) Boxed area shown in high-magnification. 3V: the third cerebral ventricle.

Figure 4. CART mRNA co-localised with c-fos neurons in the DMH after i.v. injection of RANKL. Double labeling of in situ hybridization for CART mRNA and
immunohistochemistry for c-fos expression in the DMH, 30 min after i.v. injection of RANKL. A: low-magnification. B: boxed area shown in high-magnification. Black arrows
indicate CART mRNA and red arrows indicate double-labelled c-fos and CART mRNA. 3V: the third ventricle. Scale bar: B=5μm.

Table 1. NPY and CART mRNA co-localised with c-fos neurons
NPY-GFP mice (n=4)
C57BL/6J mice (n=4)

GFP-positive cells
89.1±4.2
c-fos positive cells
42.5±4.7

GFP-positive cells expressing c-fos
47.8±3.7
c-fos positive cells expressing CART mRNA
30.3±3.5

% GFP-positive cells expressing c-fos
54.5±6.7
%c-fos positive cells expressing CART mRNA
72.5±6.5

Data represent mean ± SEM.

The expression of NPY, CART, POMC and
AgRP mRNAs in response to central
administration of RANKL
Through c-fos immunoreactivity test, we
elucidated that the Arc and DMH were influenced by
RANKL. Given that both the regions are closely
related to energy homeostasis, we detected the
expression of several neurotransmitters which
modulated energy metabolism through in situ
hybridization. Compared with control group, RANKL
treated group displayed significant decreased
expression of NPY mRNA in the Arc (Fig. 5A-C),
whereas the expression of CART mRNA in the Arc of
RANKL treated group was significantly increased

(Fig. 5D-F). In addition, no significant changes of
POMC mRNA were detected (Fig. 6A-C), even
though POMC was co-expressed with CART [28]. As
we know, AgRP is co-expressed with NPY and
capable of increasing appetite and decreasing
metabolism and energy expenditure, but there was no
significant decrease of AgRP mRNA expression in the
Arc of RANKL treated group compared with control
group (Fig. 6D-F). In the DMH, there was
up-regulation of CART mRNA expression in RANKL
group (Fig. 7A-C). These experiments revealed that
the central injection of RANKL may modulate the
expression of NPY mRNA in the Arc and CART
mRNA in the Arc and DMH to inhibit food intake and
reduce body weight.
http://www.medsci.org
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Figure 5. The RANKL influenced the expression of NPY mRNA and CART mRNA in the Arc. Bright filed micrographs of in situ hybridisation showed NPY mRNA
in the Arc, 7 days after i.c.v. injection of RANKL (A) or saline (B). Quantification of NPY mRNA expressed in the Arc comparing to saline mice (C). Bright filed micrographs of
in situ hybridisation showed CART mRNA in the DMH, 7 days after i.c.v. injection of RANKL (D) or saline (E). Quantification of CART mRNA expressed in the Arc comparing
to saline mice (F). Scale bar 200μm. Data were mean ± SEM of 5 - 6 mice each group. *** p<0.001 vs Saline controls,* p<0.05 vs. Saline controls. 3V: the third ventricle. Arc:
Arcuate nucleus

Figure 6. The RANKL did not affect POMC mRNA and AgRP mRNA expression in the Arc. Bright filed micrographs of in situ hybridisation showed POMC mRNA
in the Arc, 7 days after i.c.v. injection of RANKL (A) or saline (B). Scale bar 200μm. Quantification of POMC mRNA expressed in the Arc as a percent of saline mice (C). Bright
filed micrographs of in situ hybridisation showed AgRP mRNA in the Arc, 7 days after i.c.v. injection of RANKL (D) or saline (E). Scale bar 200μm. Quantification of CART mRNA
expressing in the Arc as a percent of saline mice (F). Data were mean ± SEM of 5 - 6 mice each group. 3V: the third ventricle. Arc: Arcuate nucleus

Figure 7. The RANKL influenced the expression of CART mRNA in the DMH. Bright filed micrographs of in situ hybridisation showed CART mRNA in the DMH, 7
days after i.v. injection of RANKL (A) or saline (B). Scale bar 100μm. Quantification of CART mRNA expressed in the DMH as a percent of saline mice (C). Data are mean ± SEM
of 5 - 6 mice each group. *** p<0.001 vs Saline controls,* p<0.05 vs Saline controls. 3V: the third ventricle.
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Discussion
Obesity is a chronic metabolic disease,
attributing to various factors, such as genetic factors,
unhealthy eating patterns, or a combination of these
factors [16]. The main pathogenesis of obesity is
energy metabolic imbalance and weight regulation
disorder.
Many
neurotransmitters
in
the
hypothalamus have been implicated in the regulation
of energy homeostasis and weight regulation [4, 21,
22, 29-31]. In our research, we verified whether NPY,
CART, POMC and AGRP were involved in the
catabolic effects via RANKL signal pathway.
RANKL, an acid peptide which can pass
through the blood brain barrier [32] and binds to
RANK expressed in the hypothalamus. RANKL
treatment significantly inhibited daily food intake
compared with control group, implying that
administration of peripheral RANKL led to altered
feeding behaviour. C-fos, a proto-oncogene which is
referred to as an immediate early gene for c-fos
mRNA and protein, is generally among the first to be
expressed after specific stimulation. We identified
changes in hypothalamic c-fos expression in response
to peripheral RANKL administration. The present
study showed there was altered expression of c-fos
compared with controls. After i.v. RANKL
administration, particularly strong increases in c-fos
expression were noted in the Arc and DMH. This
suggested that these neurons activated by RANKL
may play an important role in inhibiting food intake
and decreasing the body weight of mice.
NPY/AgRP neurons in the Arc, modulate
energy homeostasis by promoting food intake and
reducing energy expenditure [22]. Some circulating
hormones and metabolic mediators, such as leptin
and RANKL [33], can across the blood brain barrier to
reach NPY/AgRP neurons in the Arc. Food
deprivation can sharply elevate the NPY levels in the
Arc, which is capable of correcting negative energy
balance [4, 34]. I.c.v. delivery of NPY leads to robust
hyperphagia and the development of morbid obesity
[35], indicating that the NPY not only regulates
feeding but also controls energy storage. In current
study, after peripheral treatment of RANKL, there
was significant overlap in expression of Arc NPY and
c-fos labelled neurons in NPY GFP mice. In situ
hybridisation showed a down-regulation of NPY
mRNA after i.c.v. injection of RANKL. The levels of
AgRP mRNA in the Arc remained unchanged in
RANKL treated group comparing to saline injection
group. All results suggested that reduced NPY
diminished appetite, which could be a possible reason
to weight loss of mice after administration of RANKL.
As we know, CART is an orexigenic
neurotransmitter produced by POMC/CART neurons
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in the Arc. It also reduces body weight by inhibiting
food intake and increasing energy expenditure.
Fasting down-regulates CART mRNA in the Arc,
PVN and PeF [19]. Moreover, delivery of CART
strongly curbed both spontaneous and fastinginduced food intake [36]. In this study, we used
double-labelling techniques to determine the chemical
nature of neurons activated within hypothalamic
areas which were associated with energy metabolism
[37]. Approximately 72% of c-fos neurons in the DMH
were co-localised with CART mRNA after treatment
of RANKL, indicating that DMH CART neurons were
also critical in mediating anorectic effect of RANKL.
The results from in situ hybridisation showed
up-regulation of CART mRNA in the Arc and the
DMH after i.c.v. injection of RANKL, and the
expression of POMC mRNA remained almost the
same in two groups. It was possible that
administration of RANKL induced the production of
CART, which subsequently led to weight loss.
Furthermore, CART and NPY are reciprocally
regulated. NPY-stimulated feeding is blocked by
administration of CART [36, 38]. It has been
elucidated that Arc NPY neurons project to the DMH,
which influences the energy homeostasis [39-41]. In
the DMH, the neurons expressing NPY have been
found to co-express CART [42]. Moreover, NPY/
AgRP neurons can directly inhibit CART/POMC
neurons either by NPY-Y receptor activation or
release of GABA [43]. Our findings also indicate that
CART in the DMH is the downstream of NPY, which
is consistent with previous evidence [21]. Thus,
decreased Arc NPY may lead to upregulation of
CART in the DMH. In addition, after treatment of
RANKL to mice, NPY mRNA was decreased and
CART mRNA was increased in the Arc. As two sets of
neurons present reciprocal metabolic effects, the
changes of mRNA in both neurons result in inhibitory
food intake. Moreover, as the downstream of NPY,
increased CART in the DMH was regulated either by
NPY or by RANKL directly. All these findings
elucidate the possibility that RANKL has anti-obesity
effects.
In summary, the primary outcomes of this study
have provided a new understanding about the
neuronal mechanisms underlying the effects of
RANKL on food intake and energy homeostasis,
which is mediated by the hypothalamic NPY-CART
pathway. These results may provide a platform to
identify new drug targets for the development of
suitable pharmacological treatments for obesity.
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